Germany
Three new partners have joined HGF across its offices in Europe, while Carpmaels & Ransford has made UPC-focused hires in Germany
Our exclusive survey reveals German firms are failing to manage costs and develop young talent, but some counsel believe this is happening behind the scenes
Powell Gilbert’s opening in Düsseldorf, complete with a new partner hire, continues this summer’s trend of UPC-related lateral movement
IP STARS, Managing IP’s accreditation title, reveals its latest rankings for patent work, including which firms are moving up
Sponsored
Sponsored
-
Sponsored by Maiwald Intellectual PropertyKerstin Wolff and Tobias Matschke of Maiwald Intellectual Property examine a landmark Unified Patent Court decision on second medical use claims and compare it with Germany’s established approach to ‘skinny label’ products -
Sponsored by Maiwald Intellectual PropertySenior Maiwald lawyers outline the strategy behind the firm’s recognition as EPO Proceedings Firm of the Year at the Managing IP EMEA Awards 2025 and discuss key developments in the European intellectual property space
-
Sponsored by Maiwald Intellectual PropertyWilhelm Eger of Maiwald Intellectual Property examines how the Pemetrexed case has influenced European approaches to patent infringement under the doctrine of equivalency and how numbers and measurements are addressed
-
Sponsored by Maiwald Intellectual PropertyGerman courts are now permitting the service of claims on Chinese respondents by publication to ensure effective legal protection. Marco Stief of Maiwald contrasts this approach with the Unified Patent Court’s stricter stance
-
Sponsored by Maiwald Intellectual PropertyChristian Meyer and Gisela Grabow of Maiwald explore proposed changes to new EU provisions aimed at facilitating faster market entry for generics and biosimilars, so as to allegedly bolster competition and enhance patient access
-
Sponsored by Maiwald Intellectual PropertyChristian Meyer and Gisela Grabow of Maiwald discuss potential changes to the EU pharmaceutical regulation and their potential impact on data and market protection timelines for medicinal products
